Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phil Skolnick

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Neuropharmacology|September 6, 2002
An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo studyMarzena Mackowiak, Michael J O'Neill, Caroline A Hicks, et al.
Psychopharmacology|September 28, 2014
1-aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in ratsPiotr Popik, Malgorzata Holuj, Agnieszka Nikiforuk, et al.
Frontiers in Psychiatry|July 2, 2024
Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrestCeline M Laffont, Prasad Purohit, Nash Delcamp, et al.
Substance Use & Misuse|June 22, 2018
A Survey of Payer Perspectives on Cannabis Use DisorderAndrew M Kiselica, Amy Duhig, Ivan Montoya, et al.
Cureus|November 25, 2025
Post-marketing Surveillance of Intranasal Nalmefene: Prevalence and Clinical Relevance of Precipitated WithdrawalJordan Paavola, Phil Skolnick, Ann Wheeler, et al.
Journal of Clinical Pharmacology|November 17, 2004
DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profileBernard Beer, Jill Stark, Philip Krieter, et al.
CNS Drug Reviews|September 9, 2006
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitorPhil Skolnick, Philip Krieter, Joseph Tizzano, et al.
European Journal of Pharmacology|November 8, 2002
A single residue contributes sensitivity to allosteric modulation of AMPA receptors by LY395153Jennifer C Quirk, Anni-Maija Linden, Marina Strakhova, et al.
Journal of Psychiatric Research|September 20, 2011
Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trialPierre Tran, Phil Skolnick, Pal Czobor, et al.
Biochemical Pharmacology|July 12, 2012
Medication discovery for addiction: translating the dopamine D3 receptor hypothesisAmy Hauck Newman, Brandi L Blaylock, Michael A Nader, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Neuropharmacology|September 6, 2002
An AMPA receptor potentiator modulates hippocampal expression of BDNF: an in vivo studyMarzena Mackowiak, Michael J O'Neill, Caroline A Hicks, et al.
Psychopharmacology|September 28, 2014
1-aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in ratsPiotr Popik, Malgorzata Holuj, Agnieszka Nikiforuk, et al.
Frontiers in Psychiatry|July 2, 2024
Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrestCeline M Laffont, Prasad Purohit, Nash Delcamp, et al.
Substance Use & Misuse|June 22, 2018
A Survey of Payer Perspectives on Cannabis Use DisorderAndrew M Kiselica, Amy Duhig, Ivan Montoya, et al.
Cureus|November 25, 2025
Post-marketing Surveillance of Intranasal Nalmefene: Prevalence and Clinical Relevance of Precipitated WithdrawalJordan Paavola, Phil Skolnick, Ann Wheeler, et al.
Journal of Clinical Pharmacology|November 17, 2004
DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profileBernard Beer, Jill Stark, Philip Krieter, et al.
CNS Drug Reviews|September 9, 2006
Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitorPhil Skolnick, Philip Krieter, Joseph Tizzano, et al.
European Journal of Pharmacology|November 8, 2002
A single residue contributes sensitivity to allosteric modulation of AMPA receptors by LY395153Jennifer C Quirk, Anni-Maija Linden, Marina Strakhova, et al.
Journal of Psychiatric Research|September 20, 2011
Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trialPierre Tran, Phil Skolnick, Pal Czobor, et al.
Biochemical Pharmacology|July 12, 2012
Medication discovery for addiction: translating the dopamine D3 receptor hypothesisAmy Hauck Newman, Brandi L Blaylock, Michael A Nader, et al.
Pageof 6